Advertisement

Fibrohistiocytic Skin Cancers: Dermatofibrosarcoma Protuberans, Atypical Fibroxanthoma, and Undifferentiated Pleomorphic Sarcoma

  • Kavita Mariwalla
  • Allison Hanlon
Chapter

Abstract

As a group, atypical fibroxanthoma, undifferentiated pleomorphic sarcoma, and dermatofibrosarcoma protuberans (DFSP) are rare cutaneous neoplasms with the potential for significant local destruction. In DFSP, delayed diagnosis is common as the clinical presentation can appear benign. Tissue stains are key for diagnosis of dermatofibrosarcoma protuberans from the benign histologic mimicker dermatofibroma. Debate exists regarding the relationship between atypical fibroxanthoma and undifferentiated pleomorphic sarcoma. The preferred treatment for fibrohistiocytic tumors is Mohs micrographic surgery. Since close monitoring for recurrence is critical, repair options for these commonly large postsurgical defects must be carefully planned. In all cases, preoperative planning and management of patient expectation is paramount to successful therapy.

Keywords

Atypical fibroxanthoma Undifferentiated pleomorphic sarcoma Malignant fibrous histiocytoma Dermatofibroma Dermatofibrosarcoma protuberans Sarcoma 

References

  1. 1.
    Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-Sloan JS, Bordeaux JS. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016;42(1):24–31.CrossRefGoogle Scholar
  2. 2.
    Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases. Cancer. 2008;113(3):616–27.CrossRefPubMedGoogle Scholar
  3. 3.
    Connelly JH, Evans HL. Dermatofibrosarcoma protuberans. A clinicopathologic review with emphasis on fibrosarcomatous areas. Am J Surg Pathol. 1992;16(10):921–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Llombart B, Serra-Guillén C, Monteagudo C, López Guerrero JA, Sanmartín O. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol. 2013;30(1):13–28.CrossRefPubMedGoogle Scholar
  5. 5.
    Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol. 2000;24(8):1125–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Haycox CL, Odland PB, Olbricht SM, Piepkorn M. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol. 1997;37(3):438–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Calikoglu E, Augsburger E, Chavaz P, Saurat JH, Kaya G. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. J Cutan Pathol. 2003;30(3):185–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997;15(1):95–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J, Kere J, Miettinen M, Knuutila S. Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. Cytogenet Cell Genet. 2001;92(3–4):192–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Patel KU, Szabo SS, Hernandez VS, Prieto VG, Abruzzo LV, Lazar AJ, López-Terrada D. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Human Pathol. 2008;39(2):184–93.CrossRefGoogle Scholar
  11. 11.
    Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG, Gronchi A. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005;23(30):7669–75.CrossRefPubMedGoogle Scholar
  12. 12.
    Stojadinovic A, Hoos A, Karpoff HM, Leung DH, Antonescu CR, Brennan MF, Lewis JJ. Soft tissue tumors of the abdominal wall: analysis of disease patterns and treatments. Arch Surg. 2001;136(1):70–9.CrossRefPubMedGoogle Scholar
  13. 13.
    DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100(5):1008–16.CrossRefPubMedGoogle Scholar
  14. 14.
    Arnaud EJ, Perrault M, Revol M, Servant JM, Banzet P. Surgical treatment of dermatofibrosarcoma protuberans. Plast Reconstr Surg. 1997;100(4):884–95.CrossRefPubMedGoogle Scholar
  15. 15.
    Foroozan M, Sei JF, Amini M, Beauchet A, Saiag P. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol. 2012;148(9):1055–63.CrossRefPubMedGoogle Scholar
  16. 16.
    Haas RL, Keus RB, Loftus BM, Rutgers EJ, van Coevorden F, Bartelink H. The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft tissue tumours working group. Eur J Cancer. 1997;33(7):1055–60.CrossRefPubMedGoogle Scholar
  17. 17.
    Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-Sloan JS, Bordeaux JS. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016;42(Suppl 1):S24–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35(3):355–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Liang CA, Jambusaria-Pahlajani A, Karia PS, Elenitsas R, et al. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol. 2014;71(4):781–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Helwig EB, May D. Atypical fibroxanthoma of the skin with metastasis. Cancer. 1986;57(2):368–76.CrossRefPubMedGoogle Scholar
  21. 21.
    Hanlon A, et al. LN2, CD10, and Ezrin do not distinguish between atypical Fibroxanthoma and undifferentiated pleomorphic sarcoma or predict clinical outcome. Dermatol Surg. 2017;43(3):431–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Hollmig ST, Rieger KE, Henderson MT, West RB, Sundram UN. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma. Am J Dermatopathol. 2013;35(2):176–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Wingard JR, Carter SL, Walsh JT, Kurtzberg J, Small TN, Gersten ID, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients (abstract). Blood (ASH Annual Meet Abstract). 2007;110:163.Google Scholar
  24. 24.
    Lazova R, Moynes R, May D, Scott G. LN-2 (CD74) a marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer. 1997;79(11):2115–24.CrossRefPubMedGoogle Scholar
  25. 25.
    Mihic-Probst D, Zhao J, Saremasiani P, Baer A, Oehischlegel C, et al. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. Anticancer Res. 2004;24(1):19–26.PubMedGoogle Scholar
  26. 26.
    McCalmont TH. AFX: what we now know. J Cutan Pathol. 2011;38(11):853–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Ang GC, Roenigk RK, Otley CC, Kim Phillips P, et al. More than 2 decades of treating atypical fibroxanthoma at mayo clinic:what have we learned from 91 patients? Dermatol Surg. 2009;35(5):765–72.CrossRefPubMedGoogle Scholar
  28. 28.
    Love WE, Schmitt AR, Bordeaux JS. Managment of unusual cutaneous malignancies: atypical fibroxanthoma, malignant fibrous histiocytoma, sebaceous carcinoma, extramammary paget disease. Dermatol Clin. 2011;2(29):201–16.CrossRefGoogle Scholar
  29. 29.
    Hollmig ST, et al. The evolving conception and management challenges of malignant fibrous histiocytoma. Dermatol Surg. 2012;38(12):1922–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Hueterh MJ, Zitelli JA, Brodland D. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol. 2001;44(4):656–9.CrossRefGoogle Scholar
  31. 31.
    McCoppin HH, et al. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience. Dermatol Surg. 2012;38(2):230–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48(1):3–12.CrossRefPubMedGoogle Scholar
  33. 33.
    Brown MD, Swanson NA. Treatment of malignant fibrous histiocytoma and atypical fibrous xanthoma with micrographic surgery. J Dermatol Surg Oncol. 1989;15(12):1287–92.CrossRefPubMedGoogle Scholar
  34. 34.
    Withers AH, et al. Atypical fibroxanthoma and malignant fibrous histiocytoma. J Plast Reconstr Aesthet Surg. 2011;64(11):e273–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Mariwalla DermatologyWest IslipUSA
  2. 2.Department of Medicine, Division of DermatologyVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations